نتائج البحث

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

• Authors : Buggisch, Peter¹ ; Wursthorn, Karsten¹; Stoehr, Albrecht¹

Subjects: *HEPATITIS C treatment; *HEPATITIS C; *HEPATITIS C virusGERMANY; EUROPE

• Source: PLoS ONE. 4/4/2019, Vol. 14 Issue 4, p1-10. 10p.

تفاصيل العنوان

High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany.

• Authors : Müller, Jana^1,2; Schmidt, Daniel^1,2 ; Kollan, Christian¹

Subjects: *OPIOIDS; *HEPATITIS C treatment; *TUBERCULOSIS treatmentGERMANY

• Source: BMC Public Health. 10/25/2017, p1-14. 14p. 1 Diagram, 3 Charts, 1 Graph, 1 Map.

تفاصيل العنوان

Achieving an extremely high hepatitis C treatment success rate in people who inject drugs in Hai Phong, Vietnam: Results of the ANRS 12380 DRIVE-C study

• Authors : Vinh, Vu, Hai; Binh, Nguyen, Thanh; Minh Khue, Pham ...

Subjects: [SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyberlin; Germany

• Source: IAS Conference on HIV Science ; https://hal.science/hal-03922787 ; IAS Conference on HIV Science, Jul 2021, berlin, Germany

تفاصيل العنوان

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

• Authors : Stahmeyer, Jona T.¹ ; Rossol, Siegbert²; Liersch, Sebastian¹

Subjects: *HEPATITIS C treatment; *PUBLIC health; *LIVER cancerGERMANY

• Source: PLoS ONE. 1/3/2017, Vol. 12 Issue 1, p1-18. 18p.

تفاصيل العنوان

New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011.

Subjects: CONFERENCES & conventions; HEPATITIS C treatment; MEDICAL societiesBERLIN (Germany); GERMANYBRISTOL-Myers Squibb Co.

• Source: Biomedical Market Newsletter; 3/31/2011, p379-382, 4p

تفاصيل العنوان

New Hepatitis C Data from Boehringer Ingelheim HCV Portfolio to Be Presented at EASL.

Subjects: LIVER; HEPATITIS C virus; HEPATITIS C treatmentBERLIN (Germany : East); GERMANYBOEHRINGER Ingelheim GmbH

• Source: Biomedical Market Newsletter; 4/7/2011, p73-75, 3p

تفاصيل العنوان

Medivir: Week 24 Interim Results from TMC435 Hepatitis C Phase 2b ASPIRE Study presented at EASL.

Subjects: ANTIVIRAL agents; HEPATITIS C treatment; CLINICAL trialsBERLIN (Germany); GERMANYTIBOTEC BVBA; MEDIVIR AB

• Source: Biomedical Market Newsletter; 5/21/2011, p587-588, 2p

تفاصيل العنوان

Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver.

Subjects: CLINICAL trials; ANTI-infective agents; HEPATITIS C treatmentBERLIN (Germany); GERMANYACERAGEN Inc.

• Source: Biomedical Market Newsletter; 3/31/2011, p312-313, 2p

تفاصيل العنوان

Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.

• Authors : Strada, Lisa¹ ; Schulte, Bernd¹; Schmidt, Christiane Sybille¹

• Source: BMC Infectious Diseases. 12/10/2015, Vol. 15, p1-9. 9p. 2 Charts.

تفاصيل العنوان

Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs.

• Authors : Roser P; Department of Psychiatry and Psychotherapy, LVR University Hospital Essen, Medical Faculty, University of Duisburg-Essen, Virchowstr. 174, 45147, Essen, Germany.; Center for Addictive Disorders, University Hospital of Psychiatry Zurich, Medical Faculty, University of Zurich, Zurich, Switzerland.

Subjects: Substance Abuse, Intravenous*/Substance Abuse, Intravenous*/Substance Abuse, Intravenous*/complications ; Substance Abuse, Intravenous*/Substance Abuse, Intravenous*/Substance Abuse, Intravenous*/psychology ; Health Knowledge, Attitudes, Practice*

• Source: Harm reduction journal [Harm Reduct J] 2024 Aug 28; Vol. 21 (1), pp. 160. Date of Electronic Publication: 2024 Aug 28.Publisher: BioMed Central Country of Publication: England NLM ID: 101153624 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7517

تفاصيل العنوان